Lantern Pharma Secures FDA Nod to Focus NSCLC Trial on High-Need Subtype
Event summary
- FDA raised no objections to Lantern Pharma's proposed protocol amendments for the HARMONIC™ Phase 2 trial of LP-300 in never-smokers with NSCLC.
- Trial will now focus exclusively on EGFR exon 21 L858R-mutant patients, with LP-300 dosing extended to eight cycles.
- Preliminary data shows median progression-free survival of 8.3 months in the targeted subgroup.
- Lantern plans to discontinue the control arm, transitioning to a single-arm study design.
The big picture
Lantern Pharma's strategic pivot aligns with the growing recognition of never-smoker NSCLC as a distinct disease entity. The FDA's support for the amended trial design reduces regulatory risk while sharpening the focus on a high-need patient population with limited treatment options. The differentiated safety profile of LP-300 could be a key competitive advantage in a post-TKI setting where tolerability is critical.
What we're watching
- Clinical Efficacy
- Whether the enriched study design will deliver more compelling efficacy data for LP-300 in the EGFR exon 21 L858R subgroup.
- Regulatory Strategy
- How Lantern will leverage the amended trial design in discussions with regulators and potential partners.
- Commercial Differentiation
- The pace at which Lantern can position LP-300 as a best-in-tolerability option post-TKI failure.
Related topics